NRX PHARMACEUTICALS INC
NRXPNASDAQ🏆 #3922 by market capUS Equity
$2.70—
Last available close · quote unavailableTrack NRXP
Get earnings, price moves & breaking news on Telegram
24h—
7d▲ 12.5%
14d▼ 0.4%
30d▼ 7.5%
ytd▲ 0.4%
1y▼ 11.9%
🏦Market Cap
$108M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
46.6%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
31.8x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $1.62 – $5.06
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 43.3M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 31.8x
- EPS (TTM)
- $-0.74
- Dividend Yield
- —
- Dilution (1yr)
- +201.7%
NRX PHARMACEUTICALS INC
NRXPFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$16M▼ −17.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▲ +32.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.7M▲ +201.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$12M YoY
StockOtter · stockotter.spaceAbout NRX PHARMACEUTICALS INC
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.